Pura Vida Investments LLC acquired a new position in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 622,922 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,305,000. BioDelivery Sciences International accounts for about 1.4% of Pura Vida Investments LLC’s portfolio, making the stock its 23rd biggest holding. Pura Vida Investments LLC owned approximately 0.88% of BioDelivery Sciences International as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in BioDelivery Sciences International by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 517,620 shares of the specialty pharmaceutical company’s stock worth $1,915,000 after purchasing an additional 5,628 shares during the last quarter. Knott David M increased its position in BioDelivery Sciences International by 33.8% during the fourth quarter. Knott David M now owns 500,300 shares of the specialty pharmaceutical company’s stock worth $1,851,000 after buying an additional 126,300 shares during the period. Advisor Group Inc. increased its position in BioDelivery Sciences International by 56.3% during the fourth quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock worth $40,000 after buying an additional 3,943 shares during the period. Raymond James & Associates increased its position in BioDelivery Sciences International by 14.9% during the fourth quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock worth $171,000 after buying an additional 6,000 shares during the period. Finally, NEXT Financial Group Inc increased its position in BioDelivery Sciences International by 55.9% during the fourth quarter. NEXT Financial Group Inc now owns 107,650 shares of the specialty pharmaceutical company’s stock worth $398,000 after buying an additional 38,600 shares during the period. 57.02% of the stock is owned by institutional investors.

Several research firms have commented on BDSI. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of BioDelivery Sciences International in a research report on Friday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $8.00 price target on shares of BioDelivery Sciences International in a research report on Thursday. BidaskClub raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Wednesday, February 20th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $5.00 price target on shares of BioDelivery Sciences International in a research report on Thursday, January 31st. Finally, Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “strong-buy” rating and set a $4.75 price target on the stock in a research report on Wednesday, January 23rd. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $5.55.

NASDAQ:BDSI opened at $4.98 on Friday. The company has a market capitalization of $352.63 million, a PE ratio of -12.77 and a beta of 0.45. The company has a current ratio of 3.00, a quick ratio of 2.77 and a debt-to-equity ratio of 1.42. BioDelivery Sciences International, Inc. has a 12-month low of $1.70 and a 12-month high of $5.21.

In other news, Director Mark A. Sirgo sold 9,175 shares of the business’s stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $3.57, for a total value of $32,754.75. Following the transaction, the director now owns 506,187 shares of the company’s stock, valued at $1,807,087.59. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Francis E. Odonnell, Jr. sold 23,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $5.07, for a total value of $116,610.00. Following the completion of the transaction, the director now directly owns 544,187 shares in the company, valued at approximately $2,759,028.09. The disclosure for this sale can be found here. In the last three months, insiders sold 50,175 shares of company stock worth $215,265. Corporate insiders own 13.26% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Pura Vida Investments LLC Acquires New Position in BioDelivery Sciences International, Inc. (BDSI)” was originally published by Marea Informative and is owned by of Marea Informative. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.mareainformativa.com/news/2019/03/17/pura-vida-investments-llc-acquires-new-position-in-biodelivery-sciences-international-inc-bdsi.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.

Further Reading: What are the risks of holding treasury bonds?

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.